Zydus receives final approval from the USFDA for Fluconazole Tablets USP and Clobetasol Propionate Spray

Zydus Cadila has received the final approval from the USFDA to market Fluconazole Tablets USP in strengths of 50 mg, 100 mg, 150 mg and 200 mg and Clobetasol Propionate Spray, 0.05%.

Fluconazole Tablets USP which are used to treat fungal infections will be produced at the group's formulations manufacturing facility at Baddi.

Clobetasol Propionate Spray, used in the treatment of various skin disorders will be manufactured at the group's dedicated Topical plant located at Changodar, Ahmedabad.

The group now has more than 105 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.

Shares of CADILA HEALTHCARE LTD. was last trading in BSE at Rs.447.8 as compared to the previous close of Rs. 429.45. The total number of shares traded during the day was 1235766 in over 32119 trades.

The stock hit an intraday high of Rs. 460 and intraday low of 438.1. The net turnover during the day was Rs. 553545940.

Source : Equity Bulls

Keywords